Potentiation by Metyrosine of Thioridazine Effects in Chronic Schizophrenics: A Long-Term Trial Using Double-Blind Crossover Technique

Archives of General Psychiatry

Volumn 33, Issue 4, 1976, Pages 501-505

  Wålinder, Jan ^a   Skott, Annika ^a   Carlsson, Arvid ^a   Roos, Björn Erik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; THIORIDAZINE; TYROSINE; TYROSINE DERIVATIVE;

CEREBROSPINAL FLUID; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG POTENTIATION; PLASMA; SCHIZOPHRENIA; THERAPY;

AGED; CHRONIC DISEASE; CLINICAL TRIALS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HOMOVANILLIC ACID; HUMAN; HYDROXYINDOLEACETIC ACID; MALE; METHYLTYROSINES; MIDDLE AGE; SCHIZOPHRENIA; THIORIDAZINE;

EID: 0017255840     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1976.01770040061011     Document Type: Article

References (11)

1. Carlsson A, Persson T, Roos BE, et al: Potentiation of phenothiazines by α-methyltyrosine in treatment of chronic schizophrenia. J Neural Transmission 33:83-90, 1972.
2. Carlsson A, Persson T, Roos BE, et al: Further studies on the mechanism of antipsychotic action: Potentiation by α-methyltyrosine of thioridazine effects in chronic schizophrenia. J Neural Transmission 34:125-132, 1973.
3. Bleuler E: Primäre und sekundäre Symptome der Schizophrenie. Z Neurol Psychiatr 124:606-646, 1930.
4. Wing JK: The measurement of behaviour in chronic schizophrenia. Acta Psychiatr Neurol Scand 35:245-254, 1960.
5. Wing JK: A simple subclassification of chronic schizophrenia. J Ment Sci 107:862-875, 1961.
6. Curry SH, Mould GP: Gas chromatographic identification of thioridazine in plasma and a method for routine assay of the drug. J Pharm Pharmacol 21:674-677, 1969.
7. Mårtensson E, Roos BE: Serum levels of thioridazine in mental patients and healthy volunteers. Eur J Clin Pharmacol 6:181-186, 1973.
8. Sjöström R, Roos BE: 5-Hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis. Eur J Clin Pharmacol 4:170-176, 1972.
9. Ahlenius S, Engel J: Behavioural effects of haloperidol after tyrosine hydroxylase inhibition. Eur J Pharmacol 15:187-192, 1971.
10. Ahlenius S, Engel J: On the interaction between pimozide and α-methyltyrosine. J Pharm Pharmacol 25:172-174, 1973.
11. Wålinder J, Carlsson A: Potentiation of neuroleptics by catecholamine inhibitors. Br Med J 1:551-552, 1973.